Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

Description

The purpose of this study is to measure differences in diabetes control with the use of continuous glucose monitor (CGM) and diabetes education compared with standard of care for glucose monitoring (glucometer checks) and diabetes education in participants with diabetes mellitus receiving therapy with insulin and being admitted to Mayo Clinic Advanced Care at Home Program (ACH).

Conditions

Diabetes Mellitus

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to measure differences in diabetes control with the use of continuous glucose monitor (CGM) and diabetes education compared with standard of care for glucose monitoring (glucometer checks) and diabetes education in participants with diabetes mellitus receiving therapy with insulin and being admitted to Mayo Clinic Advanced Care at Home Program (ACH).

Continuous Glucose Monitor Use for Mayo Clinic Advanced Care at Home Patients With Diabetes Mellitus

Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

Condition
Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Jacksonville

Mayo Clinic in Florida, Jacksonville, Florida, United States, 32224

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients who are admitted to Advanced Care at Home (ACH) Program and supposed to remain in ACH for at least 72 hours.
  • * Patients with previous diagnosis of DM type 1 or type 2.
  • * Patients taking subcutaneous (SQ) insulin either via multidose injections or SQ insulin pump.
  • * Capable of giving signed informed consent
  • * Actively treated for diabetes ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS).
  • * Participants taking acetaminophen more than 4g per day or more than 1gm every 6 hours.
  • * Participants with altered mental status.
  • * Participants diagnosed with dementia.
  • * Patients with suicidal ideations or experiencing suicidal behavior.
  • * Patients with liver cirrhosis.
  • * Patients with End Stage Renal Disease on dialysis bot hemodialysis or peritoneal dialysis.
  • * Participants with allergy to medical grade adhesive or medical tape.
  • * Participants taking hydroxyurea.
  • * Participants who are pregnant, wanting to become pregnant, or nursing during study period.
  • * Patients with a planned MRI within the following 10 days after admission to ACH.
  • * Participants currently using continuous glucose monitor (CGM) to dose insulin or check glucose level.
  • * Participants with diabetes mellitus (DM) treated with diet alone.
  • * Participants with DM treated with oral hypoglycemic medications.
  • * Participants with DM treated with one SQ insulin injection daily.
  • * Participants enrolled in other studies addressing CGM use.
  • * Participants physically or emotionally incapable of handling a cell phone with a smart display.
  • * Participants with hearing impaired to a degree that they are not able to hear a smart phone alert or alarm.
  • * Patients lacking WIFI or Cellular coverage needed to connect the monitoring cell phone to Internet network.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mayo Clinic,

Adrian Dumitrascu, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

2025-05